IP Library Granted Patent US 12,171,785
Granted Patent B2
US 12,171,785 · App. 14/733,514 · Granted Dec 24, 2024

Pluripotent cells derived from bone marrow and methods for isolation

Inventors: Leo T. Furcht (Golden Valley, MN); Catherine M. Verfaillie (Leuven, BE); Morayma Reyes (Sammamish, WA)
Assignees: Regents of the University of Minnesota; HEALIOS K.K.
A61K35/28A61K39/461A61K39/46432C12N5/0607A61K2035/124A61K48/00A61K2239/31C12N2501/105C12N2501/11C12N2501/135C12N2501/235C12N2503/00C12N2510/00C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,171,785
App. No.
14/733,514
Granted
Dec 24, 2024
Kind
B2
Abstract

The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.

Claims (11)

1. A cell culture comprising isolated expanded human cells, the cells having undergone at least 10-40 cell doublings in culture, wherein the cells are derived from bone marrow, can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages, do not express CD45 or glyA, and express telomerase.

2. The cell culture of claim 1 wherein the telomerase-expressing cells have undergone 10 cell doublings.

3. The cell culture of claim 1 wherein the telomerase-expressing cells have undergone 20 cell doublings.

4. The cell culture of claim 1 wherein the telomerase-expressing cells have undergone 30 cell doublings.

5. The cell culture of claim 1 wherein the telomerase-expressing cells have undergone 40 cell doublings.

6. The cell culture of claim 1 wherein the cells are genetically modified.

7. The cell culture of claim 6 wherein the modification comprises introducing a selectable or screenable marker gene into the cells.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and cells obtained from the cell culture of claim 1 .

9. A method for making a pharmaceutical composition comprising admixing a pharmaceutically acceptable carrier and cells obtained from the cell culture of claim 1 .

10. A method for making the cell culture of claim 1 , said method comprising introducing the telomerase-expressing cells into cell culture medium and expanding said cells such that said cells undergo at least 10-40 cell doublings in culture.

11. The cell culture of claim 1 wherein the telomerase-expressing cells have undergone greater than 40 cell doublings.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 067606/0139 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2024
From: HEALIOS K.K.
To: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
Reel/Frame 067566/0638 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 1, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 066435/0775 →